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doi:10.1016/j.jtcvs.2003.11.076Objective: The objective of this study was to assess whether the mitral homograft
represents a valuable alternative for complete or partial mitral valve replacement.
Methods: Since 1993, 104 patients underwent mitral homograft replacement sur-
gery. The mean age was 38  15 years. The causes of mitral valve disease were
rheumatic disease (n  76), infective endocarditis (n  24), and others (n  4).
Sixty-five of these procedures were total homografts, and 39 were partial ho-
mografts.
Results: The mean follow-up was 52 35 months (maximum, 117 months). Overall
hospital mortality was 4 (3.8%) of 104 patients and 2.5% versus 8.7% for patients
without endocarditis and with endocarditis, respectively (P .19). There were 9 late
deaths (cardiac, 4; noncardiac, 5). There have been 5 early (3 months) and 10 late
reoperations. Of the remaining 77 patients, New York Heart Association class was
I in 61, II in 14, and III in 2. Four patients had endocarditis, and 5 had an ischemic
or hemorrhagic event. Freedom from major cardiac events was 71% 6% at 8 years
(partial at 81% vs total at 63%, P  .19). Among patients with a total homograft,
freedom from major cardiac events was 61%  9% and 85%  8% at 6 years in
patients younger than and older than 40 years, respectively (P  .09)
Conclusion: The risk of early dysfunction related to a mismatch between the mitral
homograft and the patient’s valve is the main pitfall of the technique. Beyond that
stage, the results were comparable with those of bioprostheses in a cohort of young
patients.
Following the original work by Sievers and colleagues,1 we described,in 1992, a technique of mitral homograft implantation in a casereport.2 Two years later, we published a series of 43 patients whounderwent partial or complete homograft replacement of the mitralvalve.3 Since that time, there have been several articles concerningearly results of mitral valve replacement with a homograft,4-8 includ-
ing some negative reports.9-11 The aim of this study was to establish the midterm
results of partial and total mitral homografts on the basis of our experience.
Methods
A total of 104 patients (67 female patients) underwent mitral homograft replacement between
February 1993 and July 2002. The mean age was 38  15 years (range, 10-69 years). The
causes of mitral valve disease were rheumatic disease (n  76), infective endocarditis (n 
24), systemic lupus erythematosis (n 1), marasmic endocarditis (n 1), congenital disease
(n 1), and degenerative disease (n 1). Assessment of valve function showed insufficiency
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CD(n  38), stenosis (n  52), and mixed disease (n  14). All
patients had an anatomic contraindication for valve repair.
Twenty-four patients had undergone previous mitral valve op-
erations (repair, n  21; replacement, n  3). Associated proce-
dures included aortic valve homograft (n  7) or repair (n  5),
tricuspid valve homograft with a mitral homograft (n  2) or
repair (n  3), reduction of left atrial cavity (n  1), closure of
atrial septal defect (n  1), and coronary artery bypass grafting
(n  1). Informed consent was obtained from all patients. The
rationale for choosing a homograft was as follows (either isolated
or combined): age less than 18 years (n  14), woman of child-
bearing age (n 38), contraindication to oral anticoagulation (n
48), and acute endocarditis (n  24).
Operative Technique
The operative technique has been described previously.3 All mitral
homografts were cryopreserved and were obtained from the As-
sistance Publique de Paris tissue Bank at Hopital Saint Louis. The
operative strategy was decided at the time of inspection. In case of
diffuse disease, a total homograft was performed (n  65). In case
of a localized lesion (calcification or abscess) with a remaining
normal or subnormal valve, a partial homograft was used (n 39).
The partial homograft techniques were anterior leaflet reconstruc-
tion with a patch of homologous leaflet (n  10) and hemivalve
replacement (n  29). In case of a hemivalve, the tailoring of the
mitral valve followed the segmentation described by Carpentier
and associates12: transplantation of A1 and P1 or A3 and P3 with
the commissure and corresponding papillary muscle. The grafted
segment was larger than the resected part so as to provide some
excess tissue.
Among patients operated on for rheumatic disease, 26 received
a partial and 50 received a total homograft (32% and 68%, respec-
tively). Among patients operated on for infective endocarditis, 13
received a partial and 11 received a total homograft (57% and
43%, respectively; P  .09 vs rheumatic disease).
In all patients prosthetic ring annuloplasty was performed. The
size ranges used were Carpentier size 36 (n 2), size 34 (n 13),
size 32 (n  27), size 30 (n  18), and size 28 (n  3) and Duran
ring size 29 (n  11) and size 27 (n  19). The mean cardiopul-
monary bypass time was 116  38 minutes, and the mean cross-
clamp time was 103  35 minutes.
Follow-up
Intraoperative transesophageal and postoperative transthoracic
echocardiography was performed in all patients. Clinical follow-up
was obtained directly from the patient, his or her general physician
and cardiologist, or both.
Statistical Analysis
Quantitative variables were expressed as means  SD. Compari-
sons between groups used the Mann-Whitney U test for quantita-
tive variables and the 2 or Fisher exact tests for qualitative
variables. Analysis of late results was performed on the 3 follow-
ing end points: survival, survival taking into account only cardiac-
related deaths, and a composite end point (freedom from major
cardiac events) associating survival with neither cardiac-related
death nor reoperation. Cumulative survival was determined for
these 3 end points according to the Kaplan-Meier method. Uni-
530 The Journal of Thoracic and Cardiovascular Surgery ● Octovariate analysis of the predictive factors of event-free survival used
a log-rank test for qualitative variables. The analysis of reoperation
alone was performed according to the actual method.13 All anal-
ysis was performed with SAS statistical software (release 6.11,
SAS Institute Inc, Cary, NC).
Results
Hospital Events
Hospital mortality (n  4). Overall hospital mortality
was 4 (3.8%) of 104 patients. These comprised 2 (2.5%) of
80 patients without endocarditis and 2 (8.7%) of 24 patients
with infective endocarditis (P  .19). Causes of death were
mitral homograft failure, cerebrovascular accident, pulmo-
nary infection, and biventricular failure. Homograft failure
resulted in a prolapse caused by either a superficial implan-
tation of the papillary muscles or a large homograft, and the
patient died before reoperation could be attempted.
Early reoperations (n  5). There were 5 early reop-
erations within 3 months because of early valve dysfunc-
tion. In 3 patients the mechanism of the early failure was a
leaflet restriction related to a deep implantation of the pap-
illary muscles or to an undersized homograft. In these 3
patients intraoperative echocardiography had revealed a
moderate degree of mitral regurgitation that had been con-
sidered acceptable.
In another case a leaflet suture dehiscence occurred at the
10th postoperative day in a patient who had undergone
replacement of an infected prosthesis in a dilated left ven-
tricle. Sizing of the homograft had been roughly estimated
from the prosthesis size. In another patient rupture of chor-
dae to the anterior leaflet occurred, probably as a result of
chordal erosion by the suture material used for papillary
muscle implantation.
The early reoperation rate was higher for total (4/65
[6.1%]) compared with partial (1/39 [2.6%]) homografts
(P  .41). This patient receiving a partial homograft had
complex lesions that required the use of 2 segments of
homograft.
Other complications. The following complications were
observed: transient cerebrovascular accident (n  1), acute
pancreatitis (n  1), pericardial effusion (n  5) with one
tamponade, and atrial flutter (n  2).
Postoperative echocardiography. Intraoperative echo-
cardiography revealed either no or trivial regurgitation in all
but 3 patients who were reported as having moderate but
acceptable regurgitation. There were no patients with mitral
stenosis, and the mean gradient immediately postopera-
tively was 4 1 mm Hg, whereas the mean orifice area was
2.3  0.4 cm2.
Late Results
Follow-up was obtained for 99 (95.1%) of 104 patients, and
a recent follow-up of less than 12 months was available in
88 patients. The mean follow-up period was 52  34
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months.
Late mortality (n  9). Nine late deaths occurred. Four
were cardiac related: recurrent infective endocarditis, pul-
monary embolus, congestive heart failure, and bleeding
during a reoperation. Five deaths were noncardiac related:
laryngeal carcinoma, bronchial carcinoma (n  2), HIV-
related sepsis, and trauma. At 8 years, freedom from all
causes of death was 80%  6%, and freedom from cardio-
vascular deaths was 91%  3% (Figure 1).
Late reoperations (n  10). Ten patients required a late
reoperation. The time range of reoperation was 18 to 96
months (mean, 53 months). Seven patients presented with
predominant mitral stenosis, and 3 had predominant mitral
regurgitation. According to the actual method, 81%  5%
of the patients were free from reoperation at 8 years.
Kaplan-Meier analysis showed that 71%  6% of the pa-
tients were free from major cardiac events at 8 years (Figure
1).
The causes for late reoperation were homograft degen-
eration in 8 patients and recurrent endocarditis in 2 patients.
In homograft degeneration the valve appeared to be severely
fibrosed, with leaflet and chordal thickening and retraction.
Occasionally, commissural, as well as chordal, fusion was
observed. Localized calcium deposits were also found on
the leaflet and at the papillary muscle implantation sites.
The papillary muscle invariably appeared to be completely
healed, with a fibrosed scar. There were no cases of chordal
or papillary muscle rupture.
The freedom from major cardiac events of partial ho-
mografts at 7 years was 81% versus 63% for total ho-
mografts (P  .19; Figure 2). The freedom from major
cardiac events was 76%  10% in the endocarditis group in
Figure 1. Eight-year results after mitral homograft implantation:
survival (all deaths, 80%; cardiac deaths, 91%), freedom from
reoperation (81%), and freedom from major cardiac events (71%).comparison with 70%  7% for the nonendocarditis group
The Journal of Thoraci(P  .65). Among patients with a total homograft, the
freedom from major cardiac events was lower in patients
younger than 40 years of age compared with patients older
than 40 years of age (61%  9% vs 85%  8% at 6 years,
respectively; P  .09; Figure 3). The instantaneous risk of
reoperation is represented in Figure 4.
Endocarditis (n  4). There were 4 patients with endo-
carditis, including 2 drug addicts, all of whom had under-
gone operations for endocarditis. One patient died before a
reoperation could be attempted. One patient was treated
successfully medically. Two patients underwent reopera-
tion, including a patient with combined replacement of both
the mitral and the tricuspid valve with 2 separate ho-
mografts.14 Recurrence of endocarditis was associated with
large and obstructive vegetation with no chordal rupture.
The underlying homograft was slightly degenerated in both
cases.
Thromboembolic and hemorrhagic events (n 
5). Three patients had late transient ischemic attacks while
in atrial fibrillation without neurologic sequelae. One pa-
tient had a thrombus on the prosthetic ring, which resolved
without reoperation. Two patients had severe bleeding
(muscular hematoma and gastrointestinal bleeding) related
to anticoagulation therapy. Both were successfully treated
medically.
Functional result. Of the 77 patients alive without re-
operation, 61 were in New York Heart Association class I,
14 were in class II, and 2 were in class III. Three patients
had successful pregnancies.
Echocardiographic study. Echocardiography was per-
Figure 2. Freedom from major cardiac events (cardiac death and
reoperation) was 81% for partial homografts and 63% for total
homografts at 7 years (P < .19). The difference is related to a
larger number of events in the early postoperative period among
patients with a total homograft.formed by the transthoracic approach in 71 of 77 patients
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9), or 3 (n  2). Five patients had mild mitral stenosis with
an orifice area of less than 1.5 cm2, and 66 patients had no
stenosis. The mean gradient across the valve was 5.6  2.4
mm Hg, with a mean orifice area of 1.7  0.4 cm2.
Histopathology
Early explants. Microscopic examination of the early
explants revealed that the normal architecture of the valve in
3 layers was preserved (Figure 5). A subacute inflammatory
cell infiltrate was noted in most cases, consisting mainly of
macrophages. There was evidence of edema and thickening
Figure 3. Freedom from major cardiac events (cardiac death and
reoperation) in patients with total homografts was 61%  9%
versus 85%  8% at 6 years in patients younger than and older
than 40 years of age, respectively (P < .09).
Figure 4. Instantaneous risk of reoperation (actual estimation),
showing a peak of reoperation during the first postoperative year
(which does not exist with bioprostheses) and a progressive
increase over 8 years (comparable with the fate of bioprosthetic
valves).of the endocardium. This was interpreted as a sign of mild
532 The Journal of Thoracic and Cardiovascular Surgery ● Octoimmunologic cell-mediated rejection. In some cases a fi-
brotic process was already present.
Late explants. Examination revealed severe leaflet fi-
brosis with degeneration and hyalinization. Discrete areas
of calcification were noted (Figure 6). The leaflet tissue
most frequently appeared to be completely acellular. The
chordae and their attachments, although slightly thickened
and fibrotic, were essentially normal, with a central core of
collagen and a lightly thickened endocardium. The papillary
muscles were fibrosed with sporadic areas of viable muscle,
and significant calcium deposits were frequently observed at
Figure 6. Histologic aspect of a mitral homograft leaflet 5 years
after implantation. Extensive fibrosis and complete acellularity is
shown, with discrete areas of calcification identified by the
purple staining.
Figure 5. Histologic aspect of a mitral homograft leaflet early
after implantation (2 months). Subacute inflammatory reaction
with edema and macrophage infiltration, resulting in thickening
of the endocardium with preservation of the normal trilaminar
architecture, is shown.this level.
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Our results show that homograft replacement of the mitral
valve can be achieved with an acceptable hospital mortality
(3.8%), although early valve failure constitutes a potential
pitfall of the technique. Almost all early reinterventions
were directly or indirectly linked to a mismatch between the
size of the homograft and that of the patient’s valve. The
mechanism of regurgitation was more frequently a restricted
leaflet motion (type III) than a leaflet prolapse (type II).15 A
leaflet suture dehiscence was observed in one patient who
had previously undergone replacement with a prosthesis.
The difficulty in assessing the size of the homograft led us
to consider the presence of a prosthesis as a relative con-
traindication for the use of a mitral homograft.
In this series the method of valve sizing relied on the
postulate that all the elements of the mitral valve are nor-
mally proportioned: leaflet dimensions, length of the chor-
dae, and diameter of the orifice. With increasing size of the
valve, all the elements would increase according to a fixed
ratio. Thus our original theory was that a precise measure-
ment of a single component of the mitral valve would allow
us to accurately size the valve. In this series the selected
criterion was the height of the anterior leaflet. This param-
eter was chosen because it was available before the opera-
tion on the patient’s mitral valve by using transesophageal
echocardiography and on the homograft by means of a
direct measure by the technicians at the tissue bank.
Soon it appeared that the height of the anterior leaflet
provided only a rough estimate of the valve size. Some
limitations have been identified: (1) the simultaneous har-
vesting of the aortic valve led to the resection of some tissue
on the anterior leaflet of the mitral valve remaining attached
to the aortic homograft, leading to an underestimation of the
true dimensions of the mitral homograft; (2) the measure-
ment of the patient’s anterior leaflet height was biased by
the limits of echocardiography, which did not offer a strictly
anteroposterior cross-section of the mitral valve, leading to
an overestimation of the valve size; and (3) because of
pathologic involvement of the recipient’s valve, the size of
the anterior leaflet did not necessarily correlate with the
dimensions of the homograft, which should be selected.
A simple alternative to the sizing method described
above would be to give up the preoperative assessment of
the patient’s valve and to use as the sole parameter the
diameter of the mitral orifice calibrated intraoperatively
with an obturator as for a prosthetic valve replacement. The
mitral homografts would be indexed at the tissue bank
according to the annulus diameter. The causes of valve
disease in this series (mitral stenosis and acute bacterial
endocarditis) do not produce any annular dilatation, and the
assessment of the diameter should truly reflect the dimen-
sions of the mitral valve.
The Journal of ThoraciThe risk of reoperation for early failure seems to be
lower with the partial homograft (2.6%) compared with that
seen with the complete homograft (6.2%). This could be due
to the fact that the importance of sizing is less critical than
for a complete graft. Indeed, by using the remaining parts of
the native valve, the reference point technique15 could be
used for guiding the implantation of the partial homograft.
There was no case of systolic anterior motion, despite the
systematic use of a small-sized prosthetic ring. As opposed
to myxoid valves, there is no excess tissue in mitral ho-
mografts, and the risk for obstruction of the left outflow
tract is low. Furthermore, once inserted, the homograft
leaflets are somewhat restricted, and the tension exerted on
the chordae usually prevented the excursion of the anterior
leaflet in systole toward the outflow tract.
The papillary muscle implantation technique used in our
series was an intraventricular fixation in a side-to-side po-
sition on the recipient papillary muscle.3 As opposed to
other series,9,16 there was no instance of papillary muscle
rupture. A rapid healing process was observed, resulting in
a stable and fibrotic attachment of the papillary muscles.
Although rarely encountered (5% of the cases), a limit of
the technique has been recognized: the subdivision of the
recipient papillary muscle in multiple underdeveloped heads
raised significant technical difficulties and should be con-
sidered as a contraindication for homograft implantation.
The adjunction of a prosthetic mitral ring to the mitral
homograft has been critical. As for mitral valve repair, it
undoubtedly improved the stability of the results. Ring
annuloplasty resulted in an increased surface of contact
between the leaflets, which reduced the traction exerted on
the subvalvular apparatus, thereby facilitating the consoli-
dation of papillary muscle anastomosis.
The most frequent cause of late valve failure was the
degeneration of the homograft. Its functional consequences
were more often a stenosis than regurgitation. The combi-
nation of a small-sized prosthetic ring with a fibrotic in-
volvement of the homograft probably accounted for the
stenosis. Surprisingly, there were no late cases of ruptured
chordae in this series, and the degenerative process invari-
ably progressed toward thickening and fibrosis rather than
fragilization and dystrophy. These changes vary from that of
the degeneration of aortic homografts, in which it is com-
mon to observe a pellucid aspect of the cusps.
The valves used in this series were stored with cryo-
preservation, and only sporadic calcium deposits were ob-
served, as opposed to the massive calcification reported for
mitral homografts preserved with other techniques (glutar-
aldehyde or formaldehyde).17 Similarly to microscopic find-
ings on aortic homografts, the mitral valves explanted late
were completely acellular. Once cryopreserved and in-
serted, it seems that the mitral homograft does not retain any
viability.
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who had undergone operations for endocarditis. Although
the use of a mitral homograft did not eliminate the risk for
endocarditis, the management of this complication was
made easier, and reoperation could occasionally be avoided.
The comparison of the outcome of partial versus total
homografts showed that beyond the early postoperative
period, the risk of death or reoperation was similar in the 2
groups. Obviously, with a partial homograft, the remaining
portion of the autologous valve was spared by the degen-
erative process, which should have improved the late out-
come. On the other hand, the quality of the remaining part
of the valve was occasionally suboptimal, particularly in
cases of rheumatic disease, and was in itself the source of
reoperation in a few cases.
On the whole, the mitral homograft offered a survival
without reoperation of 71% at 8 years in this series. The vast
majority of the patients were asymptomatic and had a nor-
mally functioning mitral valve. Thus, except for the early
period, the fate of the mitral homografts appear to be
comparable with that of mitral bioprostheses in a cohort of
young patients (Figure 4). It is known that the longevity of
bioprostheses in the mitral position is inferior to that of their
aortic counterparts because of the abrupt closure of the
mitral valve in systole.18 The present study suggests that
this observation is also true for the longevity of the ho-
mografts.
Finally, as is the case for aortic homografts,19 the dura-
bility of the mitral homograft seems to be related to the
patient’s age. At younger than 40 years of age, the freedom
from cardiac events was lower among patients with a total
homograft in our series (Figure 3). In the pediatric group
mitral valve replacement with a biologic valve still raises a
difficult problem because the bioprostheses have a very
limited durability, and it appears that the mitral homograft
degenerates rapidly also in children.11
Conclusion
Homograft replacement of the mitral valve can be achieved
with reliable long-term results in a large series of patients.
The partial homograft technique significantly enhances the
possibilities of valve repair, particularly in patients with
acute bacterial endocarditis,20 and offers good durability.
The mitral homograft carries a greater risk of early dysfunc-
tion than does a bioprosthetic valve. Beyond the first post-
operative year, the 8-year follow-up of mitral homografts
appears to provide results comparable with those of mitral
bioprostheses in a cohort of young adults. Relative contra-
indications for the procedure have been identified and in-
clude unfavorable anatomy of the recipient papillary mus-
cles, redo patients already subjected to prosthetic mitral
valve replacement, and young recipients who are still grow-
ing. Optimal valve sizing is critical, and the method used in
the past needs to be changed for a direct intraoperative
534 The Journal of Thoracic and Cardiovascular Surgery ● Octomeasurement of the annulus. By following these guidelines,
we believe that it is possible that the results of the mitral
homograft can be further improved. Meanwhile, the bio-
prosthesis and, in particular, the bovine pericardial valve21
remain the gold standard for mitral valve replacement with
a biologic substitute.
References
1. Sievers HH, Lange PE, Yankah AC, et al. Allogeneous transplantation
of the mitral valve. An open question. Thorac Cardiovasc Surg.
1986;33:227-9.
2. Acar C, Farge A, Ramsheyi A, et al. Mitral valve replacement using a
cryopreserved mitral homograft. Ann Thorac Surg. 1994;57:746-8.
3. Acar C, Tolan M, Berrebi A, et al. Homograft replacement of the
mitral valve: graft selection, technique of implantation and results in
forty-three patients. J Thorac Cardiovasc Surg. 1996;104:1274-9.
4. Kumar SA, Kumar AD, Chander H, Saxena A. Experience with
homograft mitral valve replacement. J Heart Valve Dis. 1998;2:225-8.
5. Plunkett MD, Schneider DJ, Shah JJ, Bash SE, Bond LM, Geiss DM.
Homograft replacement of mitral valve in children. Ann Thorac Surg.
1998;66:849-52.
6. Reardon MJ, Vinnerkvist A, Le Maire SA. Mitral valve homograft for
mitral valve replacement in acute bacterial endocarditis. J Heart Valve
Dis. 1999;8:71-3.
7. Doty DB, Flores JH, Doty JR, Millar RC. Mitral valve replacement
with homograft. Semin Thorac Cardiovasc Surg. 1999;11(suppl 1):
191-3.
8. Gulbins H, Anderson I, Killian E, et al. Five years of experience with
mitral valve homografts. Thorac Cardiovasc Surg. 2002;50(4):223-9.
9. Kumar AS, Choudhary SK, Mathur A, Saxena A, Roy R, Chopra P.
Homograft mitral valve replacement: five years’ results. J Thorac
Cardiovasc Surg. 2000;120:450-8.
10. Doty DB, Doty JR, Flores JH, Millar RC. Cardiac valve replacement
with mitral homograft. Semin Thorac Cardiovasc Surg. 2001;13:35-
42.
11. Chauvaud S, Waldmann T, d’Atellis N, et al. Homograft replacement
of the mitral valve in young recipients: mid-term results. Eur J Car-
diothorac Surg. 2003;23:560-6.
12. Carpentier AF, Lessana A, Relland JY, Belli E, Mihaileanu S, Berrebi
A, et al. The “Physio-ring”: an advanced concept in mitral valve
annuloplasty. Ann Thorac Surg. 1995;60:1177-86.
13. Grunkemeier GL, Wu YX. Actual versus actuarial event-free percent-
ages. J Thorac Cardiovasc Surg. 2001;72:677-8.
14. Acar C, Iung B, Cormier B, Grare P, Berrebi A, D’Attelis N, et al.
Double mitral homograft for recurrent bacterial endocarditis of the
tricuspid and mitral valves. J Heart Valve Dis. 1994;3:470-2.
15. Carpentier A. Mitral valve repair: the French “correction.” J Thorac
Cardiovasc Surg. 1983;86:323-37.
16. Yankah AC, Sievers HH, Lange PE, Bernhard A. Clinical report on
stentless mitral allografts. J Heart Valve Dis. 1995;4:40-4.
17. Tamura K, Jones M, Yamada I, Ferrans VJ. A comparison of failure
modes of glutaraldehyde-treated versus antibiotic-preserved mitral
valve allografts implanted in sheep. J Thorac Cardiovasc Surg. 1994;
110:224-38.
18. North RA, Sadler L, Stewart AW, McCowan LME, Kerr AR, White
HD. Long term survival and valve-related complications in young
women with cardiac valve replacements. Circulation. 1999;99:2669-
76.
19. Clarke DR, Campbell DN, Hayward AR, Bishop DA. Degeneration of
aortic allografts in young recipients. J Thorac Cardiovasc Surg. 1993;
105:934-42.
20. Iung B, Rousseau J, Cormier B, et al. Contemporary results of mitral
valve repair for acute or healed infective endocarditis. J Am Coll
Cardiol. 2004;43:386-92.
21. Jamieson EWR, Marchand MA, Pelletier CL, et al. Structural valve
deterioration in mitral valve replacement surgery: comparison of Car-
pentier-Edwards supra-annular porcine and perimount pericardial bio-
prostheses. J Thorac Cardiovasc Surg. 1999;118:297-305.
ber 2004
